Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients

NCT03671733 · Unknown status

Last updated 2026-05-28

This clinical trial tests the effects of GLP-1 receptor agonists (GLP-1 RAs) on weight and metabolic indicators in adults with obesity over a 3-month period.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 150 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2018-09 · est. completion 2022-09

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT03671733 ↗

Description as written by the study sponsor.

This studay evaluates the effect of the glucagon-like peptide-1 (GLP-1) receptor agonist,including Liraglutide,Exenatide and Exenatide Microspheres for Injection,in the treatment of subjects who are overweight or obese.

Treatments tested

Liraglutide also known as Victoza Drug

The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards, 1.8mg per day, subcutaneous injection.
Exenatide also known as Byetta Drug

10mcg once a day for 4 weeks increased to 10mcg twice a day for 8 weeks.
Exenatide Microspheres for Injection also known as Bydureon Drug

Exenatide 2 mg injection once weekly for 12 weeks.

Main thing measured	Weight Change at 3 months
Sponsor	Xiangya Hospital of Central South University
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03671733 ↗